The Summary
In a post hoc analysis of a 32-week randomized, double-blind, placebo-controlled trial, researchers evaluated the effects of semaglutide on biological aging. The study analyzed blood DNA methylation in 84 adults with HIV-associated lipohypertrophy (45 receiving semaglutide, 39 receiving placebo). At 32 weeks, participants on semaglutide showed significant reductions in epigenetic age across several advanced "clocks," including PhenoAge (-4.9 years) and GrimAge. Systems-based clocks also indicated slower aging in the heart, brain, and inflammatory pathways, suggesting potential systemic anti-aging benefits.
Why this is interesting
While GLP-1 drugs are famous for metabolic health, scientists have long suspected they might act as "gerotherapeutics" that delay aging. This study provides some of the first clinical trial evidence that semaglutide physically slows biological aging at the cellular level. Though the study was modest and focused on adults with HIV, it opens a revolutionary door: these blockbuster drugs might not just manage disease, but could actually keep our tissues and organs biologically younger for longer.